BioInvent International AB, of Lund, Sweden, initiated Phase I/IIa studies of BI-201 to treat HIV infection. The first patients at Chelsea & Westminster Hospital in London have received the first dose. The trial will assess safety, tolerability and …
No comments:
Post a Comment